Company profile
ARVINAS, INC.
NASDAQ:ARVNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Vepdegestrant | approved | — | 9 | approved |
| BAVDEGALUTAMIDE | phase1_2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04072952 | phase1_2 | completed | 2019-08-05 | 2024-09-13 | Arvinas Estrogen Receptor, Inc. | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
| NCT06393738 | phase1 | recruiting | 2024-09-05 | 2028-03-01 | Arvinas Inc. | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. |
| NCT07749586 | phase1_2 | recruiting | 2026-07-29 | 2031-03-31 | Arvinas Inc. | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors |
| NCT07023731 | phase1_2 | active_not_recruiting | 2025-05-29 | 2026-11-30 | Arvinas Inc. | A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation |
| NCT05549505 | phase2 | completed | 2023-02-15 | 2024-07-13 | Arvinas Inc. | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery |
FDA applications (0)
No records yet.